PROTHENA CORPORATION PLC - ORDINARY SHARES

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

05 4 2024 09:45:33 提供 NetDania Notify

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

04 4 2024 12:49:03 提供 NetDania Notify

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

03 4 2024 09:45:03 提供 NetDania Notify

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

02 4 2024 10:53:49 提供 NetDania Notify

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

28 3 2024 10:42:06 提供 NetDania Notify

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

27 10 2022 16:05:01 提供 Nasdaq GlobeNewswire

Prothena to Participate in Upcoming Healthcare Conferences

01 9 2022 16:20:00 提供 Nasdaq GlobeNewswire

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

01 9 2022 16:05:00 提供 Nasdaq GlobeNewswire

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

08 8 2022 16:05:02 提供 Nasdaq GlobeNewswire

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 8 2022 16:05:01 提供 Nasdaq GlobeNewswire

Prothena to Report Second Quarter 2022 Financial Results on August 8th

01 8 2022 16:05:01 提供 Nasdaq GlobeNewswire

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 7 2022 16:16:52 提供 Nasdaq GlobeNewswire

Prothena to Participate in Jefferies Healthcare Conference

02 6 2022 16:05:00 提供 Nasdaq GlobeNewswire

Prothena Reports First Quarter 2022 Financial Results and Business Highlights

05 5 2022 16:05:05 提供 Nasdaq GlobeNewswire

Prothena to Report First Quarter 2022 Financial Results on May 5th

28 4 2022 16:05:00 提供 Nasdaq GlobeNewswire

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

26 4 2022 08:30:00 提供 Nasdaq GlobeNewswire

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

28 3 2022 08:30:00 提供 Nasdaq GlobeNewswire

Prothena to Participate in Stifel 2022 Virtual CNS Days

21 3 2022 16:05:00 提供 Nasdaq GlobeNewswire

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022

16 3 2022 05:30:00 提供 Nasdaq GlobeNewswire

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

17 2 2022 16:05:01 提供 Nasdaq GlobeNewswire